English
Polski
Español
українська
Is any of the SGLT-2 inhibitors more “kidney friendly” than others?
Is any of the SGLT-2 inhibitors more “kidney friendly” and should therefore be preferred by nephrologists?
2023-06-22
Is any of the SGLT-2 inhibitors more “kidney friendly” and should therefore be preferred by nephrologists?
Do you think that in the near future GLP-1 receptor agonists and finerenone will also be used in patients with nondiabetic CKD?
What is your prediction on the role of the new H+ ion–binding drug veverimer in nephroprotection?
In the context of the latest data on the efficacy of SGLT-2 inhibitors in CKD, do you think that an ACE inhibitor/ARB must always be used first, or can an SGLT-2 inhibitor be the upfront treatment?
If you were to name the 3 most important recent advances in nephrology that are relevant for everyday practice, what would they be?
Dr Alistair Ingram from St. Joseph’s Healthcare Hamilton shares his views on the most positive shifts in care for patients with chronic kidney disease and end-stage renal disease.
Dr Jürgen Floege from the University Hospital RWTH Aachen, Germany, shares his view on the 3 most important recent advances in nephrology.
Is kidney transplantation contraindicated in obese patients?
When should we start dialysis in a patient with acute kidney injury (AKI)?
Do you think that inhibitors of renal sodium-glucose cotransporter-2 (SGLT-2) will become, or already are, the key drugs for patients with diabetes and chronic kidney disease?
